RICOLINOSTAT (ACY-1215) THE FIRST SELECTIVE HDAC6 INHIBITOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED & REFRACTORY MULTIPLE MYELOMA: PHASE 1B & EARLY PHASE 2 RESULTS

被引：0
|
作者：
Raje, N. [1 ]
Bensinger, W. [2 ]
Lebovic, D. [3 ]
Lonial, S. [4 ]
Jagannath, S. [5 ]
Acre-Lara, C. [6 ]
Rosko, A. [7 ]
Harb, W. [8 ]
Bahlis, N. [9 ]
Supko, J. [1 ]
Tamang, D. [10 ]
Jones, S. [10 ]
Wheeler, C. [10 ]
Richardson, P. [11 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
[4] Emory Univ, Atlanta, GA 30322 USA
[5] Mt Sinai Hosp, New York, NY 10029 USA
[6] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[7] Ohio State Univ, Columbus, OH 43210 USA
[8] Horizon Oncol Ctr, Lafayette, IN USA
[9] Tom Baker Canc Clin, Calgary, AB, Canada
[10] Acetylon Pharmaceut Inc, Boston, MA USA
[11] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P279
引用
收藏
页码：86 / 86
页数：1
相关论文
共 50 条
  • [41] A Phase 1b/2a Study of the CELMoD Iberdomide (CC-220) in Combination With Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Lonial, Sagar
    Van de Donk, Niels
    Popat, Rakesh
    Zonder, Jeffrey A.
    Minnema, Monique
    Larsen, Jeremy T.
    Tuong Vi Nguyen
    Chen, Min S.
    Bensmaine, Amine
    Peluso, Teresa
    Sonneveld, Pieter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E52 - E53
  • [42] Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
    Biran, Noa
    Siegel, David
    Berdeja, Jesus G.
    Raje, Noopur
    Cornell, Robert Frank
    Alsina, Melissa
    Kovacsovics, Tibor
    Fang, Belle
    Kimball, Amy S.
    Landgren, Ola
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (07) : 794 - 802
  • [43] A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma
    Martin, Thomas
    Baz, Rachid
    Benson, Don M.
    Lendvai, Nikoletta
    Wolf, Jeffrey
    Munster, Pamela
    Lesokhin, Alexander M.
    Wack, Claudine
    Charpentier, Eric
    Campana, Frank
    Vij, Ravi
    BLOOD, 2017, 129 (25) : 3294 - 3303
  • [44] PHASE 1B STUDY OF VENETOCLAX COMBINED WITH BORTEZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Moreau, P.
    Chanan-Khan, A.
    Roberts, A. W.
    Agarwal, A.
    Facon, T.
    Kumar, S.
    Touzeau, C.
    Diehl, S.
    Cordero, J.
    Ross, J.
    Munasinghe, W.
    Zhu, M.
    Salem, A. H.
    Leverson, J.
    Maciag, P.
    Verdugo, M.
    Harrison, S. J.
    HAEMATOLOGICA, 2016, 101 : 81 - 82
  • [45] Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients: A Multicenter, Open Label Phase 1/2 Study
    Bringhen, Sara
    Oliva, Stefania
    Liberati, Anna Marina
    Belotti, Angelo
    Larocca, Alessandra
    Bonello, Francesca
    Gaidano, Gianluca
    Bertazzoni, Paola
    Esma, Fabrizio
    Stocchi, Raffaella
    Malfitano, Alessandra
    Ribolla, Rossella
    Di Sano, Chiara
    Aschero, Simona
    Patriarca, Francesca
    De Paoli, Lorenzo
    Cafro, Anna Maria
    Sonneveld, Pieter
    Palumbo, Antonio
    Boccadoro, Mario
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E59 - E59
  • [46] a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Berenson, James
    Stampleman, Laura
    Bessudo, Alberto
    Rosen, Peter J.
    Klein, Leonard M.
    Woliver, Thomas
    Flam, Marshall S.
    Eshaghian, Shahrooz
    Nassir, Youram
    Regina, Swift A.
    James, Wang
    Benjamin, Eades
    Spektor, Tanya M.
    Vescio, Robert
    BLOOD, 2015, 126 (23)
  • [47] Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)
    Chari, Ajai
    Lonial, Sagar
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    Oriol, Albert
    Otero, Paula Rodriguez
    Pineiro, Luis
    Jakubowiak, Andrzej
    Olyslager, Yunsi
    Wang, Jianping
    Nnane, Ivo
    Ukropec, Jon
    Shreeve, Martin
    Qi, Ming
    Moreau, Philippe
    BLOOD, 2019, 134
  • [48] A multicenter, phase Ib study of subcutaneous administration of isatuximab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
    Quach, Hang
    Parmar, Gurdeep
    Ocio, Enrique M.
    Prince, H. Miles
    Oriol, Albert
    Crowther, Helen
    Tsukada, Nobuhiro
    Bories, Pierre
    Madan, Sumit
    Nathwani, Nitya
    Sunami, Kazutaka
    Semiond, Dorothee
    Yu, Disa
    Cordero, Paul
    Mace, Sandrine
    Suzan, Florence
    Moreau, Philippe
    HAEMATOLOGICA, 2024, 109 (12) : 4078 - 4082
  • [49] Phase 2 Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone As Salvage Therapy in Relapsed/Refractory Multiple Myeloma: Stage I Results
    Costello, Caitlin L.
    Brookhart, Benjamin
    Wieduwilt, Matthew J.
    Shah, Nina
    Mulroney, Carolyn
    Ball, Edward D.
    BLOOD, 2020, 136
  • [50] A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.
    Gasparetto, Cristina
    Green, Michael
    Srinivasan, Anandgopal
    Kang, Yubin
    Rizzieri, David A.
    Decastro, Carlos
    Diehl, Louis F.
    Beaven, Anne
    Li, Zighuo
    Rao, Arati V.
    Garrett, Anderson
    Tuchman, Sascha
    Long, Gwynn D.
    BLOOD, 2015, 126 (23)
12345